Inhibikase acquires CorHepta for $15M in stock; appoints Cabell as President and Adams as CSO

Inhibikase Therapeutics, Inc.

Acquired CorHepta for $15M in stock: 4,979,101 shares issued (3,319,397 upfront, remainder contingent on milestone).
Chris Cabell appointed President & Head of R&D; former CorHepta CEO and ex-CMO of Arena Pharmaceuticals.
Vincent Aurentz appointed to Board; former EVP/Chief Business Officer at Arena (acquired by Pfizer for $6.7B).
John Adams appointed Chief Scientific Officer; co-founder of CorHepta, former Head of Research at Arena.
Dr. Cabell employment: $500K base, 45% bonus, 2.81M stock options vesting over 4 years.

item 1.01 item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vincent Aurentz

Class I director

IKT · Inhibikase Therapeutics, Inc.

Filed: February 24, 2025, 6:59 PM ET

The Board also expanded its size from seven to eight directors and appointed Vincent Aurentz to serve as a Class I director of the Board.

Appointed

Chris Cabell

President and Head of Research and Development

IKT · Inhibikase Therapeutics, Inc.

Filed: February 24, 2025, 6:59 PM ET

the Board appointed Chris Cabell as President and Head of Research and Development of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vincent Aurentz was appointed as Class I director at Inhibikase Therapeutics, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

The Board also expanded its size from seven to eight directors and appointed Vincent Aurentz to serve as a Class I director of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Cabell was appointed as President and Head of Research and Development at Inhibikase Therapeutics, Inc..

Action: appointed
Role: President and Head of Research and Development

Exact text from the filing

the Board appointed Chris Cabell as President and Head of Research and Development of the Company.

View on SEC.gov

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-032821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.